Shandong Sinobioway Biomedicine Co Ltd (002581) — Net Asset Quality Index
Shandong Sinobioway Biomedicine Co Ltd (002581) has a Net Asset Quality Index of 90.0% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥2.21 Billion minus total liabilities of CN¥221.51 Million yields net assets of CN¥1.99 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check Shandong Sinobioway Biomedicine Co Ltd (002581) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Shandong Sinobioway Biomedicine Co Ltd Net Asset Quality Index Over Time (2007–2024)
This chart shows how Shandong Sinobioway Biomedicine Co Ltd's Net Asset Quality Index has evolved across 18 annual periods from 2007 to 2024. As of September 2025, the index stands at 90.0%, representing net assets of CN¥1.99 Billion against total assets of CN¥2.21 Billion CNY. See working capital to net assets of Shandong Sinobioway Biomedicine Co Ltd to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Shandong Sinobioway Biomedicine Co Ltd (2007–2024)
The table below presents the year-by-year Net Asset Quality Index for Shandong Sinobioway Biomedicine Co Ltd from 2007 to 2024, covering 18 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Shandong Sinobioway Biomedicine Co Ltd market cap and net worth.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 92.1% | CN¥2.02 Billion | CN¥2.20 Billion | CN¥173.61 Million | ▼ -0.9 pp |
| 2023 | 93.0% | CN¥2.17 Billion | CN¥2.34 Billion | CN¥163.41 Million | ▲ +6.6 pp |
| 2022 | 86.4% | CN¥2.47 Billion | CN¥2.86 Billion | CN¥389.46 Million | ▼ -3.2 pp |
| 2021 | 89.6% | CN¥2.47 Billion | CN¥2.76 Billion | CN¥286.76 Million | ▼ 0.0 pp |
| 2020 | 89.6% | CN¥2.19 Billion | CN¥2.44 Billion | CN¥254.33 Million | ▲ +19.6 pp |
| 2019 | 70.0% | CN¥2.39 Billion | CN¥3.41 Billion | CN¥1.03 Billion | ▲ +4.3 pp |
| 2018 | 65.7% | CN¥2.82 Billion | CN¥4.29 Billion | CN¥1.47 Billion | ▼ -7.3 pp |
| 2017 | 73.0% | CN¥2.92 Billion | CN¥4.00 Billion | CN¥1.08 Billion | ▼ -21.0 pp |
| 2016 | 94.0% | CN¥2.53 Billion | CN¥2.69 Billion | CN¥160.16 Million | ▲ +5.3 pp |
| 2015 | 88.7% | CN¥2.14 Billion | CN¥2.42 Billion | CN¥271.92 Million | ▼ -8.6 pp |
| 2014 | 97.4% | CN¥749.40 Million | CN¥769.49 Million | CN¥20.08 Million | ▲ +2.0 pp |
| 2013 | 95.4% | CN¥738.31 Million | CN¥773.80 Million | CN¥35.49 Million | ▼ -1.2 pp |
| 2012 | 96.6% | CN¥704.41 Million | CN¥729.02 Million | CN¥24.62 Million | ▼ -0.8 pp |
| 2011 | 97.4% | CN¥672.28 Million | CN¥690.19 Million | CN¥17.91 Million | ▲ +12.8 pp |
| 2010 | 84.6% | CN¥177.34 Million | CN¥209.68 Million | CN¥32.34 Million | ▲ +5.9 pp |
| 2009 | 78.6% | CN¥129.71 Million | CN¥164.95 Million | CN¥35.24 Million | ▼ -2.3 pp |
| 2008 | 80.9% | CN¥116.12 Million | CN¥143.53 Million | CN¥27.41 Million | ▼ -7.0 pp |
| 2007 | 87.9% | CN¥83.94 Million | CN¥95.54 Million | CN¥11.60 Million | — |